By early September 2026, daraxonrasib was already widely available to patients through prescription and expanded access programs, reflecting a rapid transition from late-stage trials to clinical practice.
But the fight is not just about one drug. Immuneering took a different approach. Instead of chasing quick tumor shrinkage, their team focused on keeping patients alive longer. Their drug, atebimetinib, is a deep cyclic inhibitor. It targets a cell survival pathway in pulses. This lets healthy cells recover while starving cancer cells of the signals they need. In a Phase 2a trial, atebimetinib plus chemotherapy gave a six-month survival rate of 94 percent among 34 patients. That number stands out. It’s far above what’s usually seen.
Immuneering has now moved atebimetinib into a global randomized pivotal trial called MAPKeeper 301. This study combines the drug with modified gemcitabine and nab-paclitaxel (mGnP). By September 2026, the company confirmed the trial had reached the ESMO Congress 2026 for presentation. The protocol, NCT07562152, is now a major focus in the field. Details are in a Nasdaq press release. The momentum is real.
Recent reviews highlight that Johns Hopkins and other leading centers are now actively investigating therapeutic vaccines for pancreatic cancer in early clinical programs, including ELI-002 2P and autogene cevumeran, particularly in the post-surgical setting.
Vaccine research is moving fast. At Johns Hopkins, Elizabeth Jaffee’s group tested a peptide-based vaccine for people at high risk with pancreatic lesions. The vaccine triggered specific immune responses. It also slowed lesion growth. This is proof that preventive immunization could work in pancreatic cancer.
Physical barriers are falling too. Ronald Evans at the Salk Institute built on mouse studies showing that turning on the vitamin D receptor in pancreatic fibroblasts can stop the dense fibrosis that protects tumors from chemotherapy. In patients, the vitamin D agonist paricalcitol, given with chemotherapy, was safe. Patients with higher vitamin D receptor expression did better. This suggests some could benefit from this combo.
Diet is under the microscope. Davide Ruggero’s team at UCSF found that fasting and ketogenic diets in mice increased phosphorylation of eIF4E, which led to more ketone bodies. Pancreatic tumors can use these for energy. The team tested a drug that blocks phosphorylated eIF4E along with a ketogenic diet. Tumor growth dropped in mice, but only with the diet. This hints at future drug-diet combos for cancer care.
Other cancers are seeing similar tactics. As reported earlier, making tumors visible to the immune system has helped in other hard-to-treat cancers.
The message is clear. Pancreatic cancer is no longer a single, untouchable enemy. Scientists are picking apart its defenses, using its own biology against it, and bringing the immune system into the fight. The data are still early. Not every patient will see the same results. But the field is moving from small steps to real change. For patients and doctors who have faced only grim odds, these results bring hope. Time is finally on their side.
